102
Views
0
CrossRef citations to date
0
Altmetric
Editorial

Bioengineered Solutions to Improve Cancer Immunotherapies

ORCID Icon & ORCID Icon
Pages 339-341 | Received 02 Feb 2021, Accepted 05 Mar 2021, Published online: 17 Mar 2021
 

Author contributions

OA Mandrup and KA Howard wrote the manuscript. All authors have read and approved the final manuscript.

Financial & competing interests disclosure

The authors would like to acknowledge CEMBID (Center for Multifunctional Biomolecular Drug Design, Grant Number: NNF17OC0028070) for funding to OA Mandrup and KA Howard. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.